Belimumab Linked to Lower Relapse Risk in Lupus Serositis
A study has found that belimumab is associated with a lower risk of relapse in patients with systemic lupus erythematosus experiencing serositis. Nearly half of the patients in the study experienced multiple relapses, with no significant difference in response rates between corticosteroid-based and corticosteroid-free therapies. The findings suggest that belimumab may be a viable treatment option for those with relapsing serositis.
- ▪The study included 100 adult patients with systemic lupus erythematosus and documented serositis episodes.
- ▪Conventional immunosuppressants did not reduce the risk of serositis relapse, while belimumab showed a significant reduction in risk.
- ▪Nearly half of the patients experienced multiple serositis relapses during follow-up, with a median time to first relapse of 0.83 years.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/belimumab-linked-lower-relapse-risk-patients-lupus-related-2026a1000gm3?src=rss |
| Publication time | Mon, 25 May 2026 08:00:00 EDT |
| Retrieval time | 2026-05-25T12:07:36.708Z |
| Last seen | 2026-05-25T12:07:36.708Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | JoDmCNV3x2HL |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with systemic lupus erythematosus (SLE) with serositis episodes, nearly half experienced relapses, with no difference in the response rate between corticosteroid-based and corticosteroid-free anti-inflammatory therapies. Conventional immunosuppressants were not associated with a reduced risk for serositis relapse, whereas belimumab was associated with a lower risk.METHODOLOGY:Researchers conducted a multicentre, real-world, retrospective observational study to assess the efficacy of anti-inflammatory and immunosuppressive therapies in SLE-related serositis.They included 100 adult patients with SLE (mean age at diagnosis, 32.9 years; 80% women) who had documented pericarditis or pleuritis between January 2000 and October 2025 based on clinical and/or imaging…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
